A prospective randomized trial of α2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma

K. Foon; J. Doroshow; E. Bonnem; A. Fefer; S. Graham; B. Grosh; P. Narayan; L. Elias; Harold Harvey; R. Schulof; R. Williams; J. Rinehart; P. Zekan; W. Catalona; R. Dillman; S. Salmon; F. Galasso

A prospective randomized trial of α_2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma

K. Foon, J. Doroshow, E. Bonnem, A. Fefer, S. Graham, B. Grosh, P. Narayan, L. Elias, Harold Harvey, R. Schulof, R. Williams, J. Rinehart, P. Zekan, W. Catalona, R. Dillman, S. Salmon, F. Galasso

Department of Medicine

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

Eighty-nine patients with advanced measurable metastatic renal cell carcinoma were entered into a prospective randomized trial comparing alpha-interferon to gamma-interferon and to the combination. The trial was performed in order to confirm the activity of gamma-interferon and assess the potential clinical synergism. Response rates were 5, 10, and 5%, respectively. The low response rate may have been due to the inability to raise the doses of the interferons to higher levels. Clinical synergy at this dose, route, and schedule of administration in renal cell carcinoma does not exist.

Original language	English (US)
Pages (from-to)	540-545
Number of pages	6
Journal	Journal of Biological Response Modifiers
Volume	7
Issue number	6
State	Published - Dec 1988

All Science Journal Classification (ASJC) codes

Immunology
Pharmacology
Cancer Research

Cite this

Foon, K., Doroshow, J., Bonnem, E., Fefer, A., Graham, S., Grosh, B., Narayan, P., Elias, L., Harvey, H., Schulof, R., Williams, R., Rinehart, J., Zekan, P., Catalona, W., Dillman, R., Salmon, S., & Galasso, F. (1988). A prospective randomized trial of α_2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma. Journal of Biological Response Modifiers, 7(6), 540-545.

@article{f2cef0eae0da46beaf69f8e6f23df321,

title = "A prospective randomized trial of α2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma",

abstract = "Eighty-nine patients with advanced measurable metastatic renal cell carcinoma were entered into a prospective randomized trial comparing alpha-interferon to gamma-interferon and to the combination. The trial was performed in order to confirm the activity of gamma-interferon and assess the potential clinical synergism. Response rates were 5, 10, and 5%, respectively. The low response rate may have been due to the inability to raise the doses of the interferons to higher levels. Clinical synergy at this dose, route, and schedule of administration in renal cell carcinoma does not exist.",

author = "K. Foon and J. Doroshow and E. Bonnem and A. Fefer and S. Graham and B. Grosh and P. Narayan and L. Elias and Harold Harvey and R. Schulof and R. Williams and J. Rinehart and P. Zekan and W. Catalona and R. Dillman and S. Salmon and F. Galasso",

year = "1988",

month = dec,

language = "English (US)",

volume = "7",

pages = "540--545",

journal = "Journal of Biological Response Modifiers",

issn = "0732-6580",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

Foon, K, Doroshow, J, Bonnem, E, Fefer, A, Graham, S, Grosh, B, Narayan, P, Elias, L, Harvey, H, Schulof, R, Williams, R, Rinehart, J, Zekan, P, Catalona, W, Dillman, R, Salmon, S & Galasso, F 1988, 'A prospective randomized trial of α_2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma', Journal of Biological Response Modifiers, vol. 7, no. 6, pp. 540-545.

TY - JOUR

T1 - A prospective randomized trial of α2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma

AU - Foon, K.

AU - Doroshow, J.

AU - Bonnem, E.

AU - Fefer, A.

AU - Graham, S.

AU - Grosh, B.

AU - Narayan, P.

AU - Elias, L.

AU - Harvey, Harold

AU - Schulof, R.

AU - Williams, R.

AU - Rinehart, J.

AU - Zekan, P.

AU - Catalona, W.

AU - Dillman, R.

AU - Salmon, S.

AU - Galasso, F.

PY - 1988/12

Y1 - 1988/12

N2 - Eighty-nine patients with advanced measurable metastatic renal cell carcinoma were entered into a prospective randomized trial comparing alpha-interferon to gamma-interferon and to the combination. The trial was performed in order to confirm the activity of gamma-interferon and assess the potential clinical synergism. Response rates were 5, 10, and 5%, respectively. The low response rate may have been due to the inability to raise the doses of the interferons to higher levels. Clinical synergy at this dose, route, and schedule of administration in renal cell carcinoma does not exist.

AB - Eighty-nine patients with advanced measurable metastatic renal cell carcinoma were entered into a prospective randomized trial comparing alpha-interferon to gamma-interferon and to the combination. The trial was performed in order to confirm the activity of gamma-interferon and assess the potential clinical synergism. Response rates were 5, 10, and 5%, respectively. The low response rate may have been due to the inability to raise the doses of the interferons to higher levels. Clinical synergy at this dose, route, and schedule of administration in renal cell carcinoma does not exist.

UR - http://www.scopus.com/inward/record.url?scp=0023737411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023737411&partnerID=8YFLogxK

M3 - Article

C2 - 3145964

AN - SCOPUS:0023737411

SN - 0732-6580

VL - 7

SP - 540

EP - 545

JO - Journal of Biological Response Modifiers

JF - Journal of Biological Response Modifiers

IS - 6

ER -

A prospective randomized trial of α_2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this